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Abstract.
Background:Down syndrome (DS; trisomy 21) individuals have a spectrum of hematopoietic and neuronal dysfunctions and
by the time they reach the age of 40 years, almost all develop Alzheimer’s disease (AD) neuropathology which includes senile
plaques and neurofibrillary tangles. Inflammation and innate immunity are key players in AD and DS. Triggering receptor
expressed in myeloid cells-2 (TREM2) variants have been identified as risk factors for AD and other neurodegenerative
diseases.
Objective: To investigate the effects of TREM2 and the AD-associated R47H mutation on brain pathology and hematopoietic
state in AD and DS.
Methods: We analyzed peripheral blood, bone marrow, and brain tissue from DS, AD, and age-matched control subjects
by immunohistochemistry and western blotting. TREM2-related phagocytosis was investigated using a human myeloid cell
line.
Results: TREM2 protein levels in brain and sera declined with age and disease progression in DS. We observed soluble
TREM2 in brain parenchyma that may be carried by a subset of microglia, macrophages, or exosomes. Two DS cases had
the AD-associated TREM2-R47H mutation, which manifested a morphologically extreme phenotype of megakaryocytes and
erythrocytes in addition to impaired trafficking of TREM2 to the erythroid membrane. TREM2 was shown to be involved
in phagocytosis of red blood cells. TREM2 was seen in early and late endosomes. Silencing TREM2 using siRNA in THP1
cells resulted in significant cell death.
Conclusion: We provide evidence that peripheral TREM2 originating from erythromyeloid cells significantly determines
AD neuropathology in DS subjects. Understanding the molecular signaling pathways mediated by TREM2 may reveal novel
therapeutic targets.
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INTRODUCTION
Down syndrome (DS) is an aneuploidy due to
trisomy 21, where genes such as amyloid precur-
sor protein (APP) are encoded in triplicate and play
key roles in the pathogenesis of Alzheimer’s disease
(AD). By the time individuals with DS reach the age
of 40 years, most develop the neuropathological fea-
tures of AD, including senile (amyloid) plaques and
neurofibrillary tangles [1–5].
Although dysfunction of amyloid- protein pre-
cursor (APP) processing is believed to be the
key upstream factor in the pathogenesis of AD
[6], neuroinflammation and activation of innate
immunity are considered early events in the gen-
esis of a variety of neurodegenerative diseases
[7, 8]. Younger DS subjects experience higher
rates of infections, hematopoietic dysregulation,
and hematological malignancies, including acute
myeloid leukemia, which are evidence for a spectrum
of immunological and inflammatory disturbances
[9–11]. During adulthood, DS individuals are also at
increased risk of developing numerous hematological
abnormalities including leucopenia, macrocytosis,
platelet defects, and persistent abnormal erythrocy-
tosis; some of these diseases are characterized by
an abundance of blasts cells in the peripheral blood
[12]. Such hematological and immunological periph-
eral factors could influence the onset or development
of AD pathology in DS.
Triggering receptor expressed on myeloid cells
2 (TREM2), a gene expressed in myeloid progeni-
tors, encodes a type I transmembrane glycoprotein
with an extracellular immunoglobulin (Ig) domain.
TREM2 signaling is facilitated by association to tyro-
sine kinase-binding protein (TYROBP, or “DAP12”),
involved in a variety of receptor signaling pathways.
Mature TREM2 protein is approximately 40 kDa
in weight. Cleaved forms of TREM2 generated
through alternate splicing are found in various tis-
sue macrophages and monocyte-derived dendritic
cells [13, 14]. Genome-wide association studies have
shown that a rare mutation of TREM2 (R47H) cor-
relates with a heightened risk of developing AD
[15–17]. Homozygosity of other mutations inTREM2
or DAP12 cause a rare form of dementia with
bone abnormalities called Nasu-Hakola disease (or
polycystic lipomembranous osteodysplasia with scle-
rosing leukoencephalopathy) [18, 19]. The role of
TREM2 in DS and its relationship to dementia in
DS has not been fully elucidated. In vitro studies
indicate that TREM2 deficiency reduces the efficacy
of amyloid clearance [20] and thus can contribute to
AD pathogenesis. We recently reported that TREM2
plays a critical role in inflammation and is essen-
tial for neuroplasticity and myelination in an AD
transgenic mouse model [21]. TREM2 deficiency
has also been demonstrated to augment amyloid-
(A) accumulation and neuronal loss in a differ-
ent mouse model of AD [22]. Previous reports
have described haplodeficiency of microglia-specific
TREM2 markedly impairing the ability of microglia
to compact and insulate amyloid deposits [23–25].
However, there are still important questions regard-
ing the origin of TREM2 detected in the brain and
the possible link between peripheral TREM2 and
resident microglia in the brain. The aim of this
study was to investigate whether soluble TREM2
can be transported across the blood-brain barrier by
peripheral cells. We also aimed to understand the
role of TREM2 and its association with hemopoi-
etic cells in DS and AD patients. To investigate the
neuropathology and involvement of TREM2 protein
in AD and DS, serum samples, blood smears from
living DS subjects, and postmortem brain sections
of individuals with AD, DS, and age-matched con-
trols (from Cambridge Brain bank, see Table 1) were
analyzed for TREM2 protein levels. Additionally,
we report the phenotypic expression of TREM2 and
other AD-relevant proteins: A42 and apolipopro-
tein E (APOE) in hemopoietic cells and brain
tissue.
We show for the first time that soluble TREM2
originating from bone marrow is transported to the
brain parenchyma by a subset of macrophages via
exosomes.
We demonstrate impaired trafficking of TREM2 to
the plasma membrane of erythrocytes in DS, which
may influence both peripheral and central amyloid
clearance pathways thought to be important in AD
pathogenesis.
To characterize the presence of any TREM2 R47H
mutations, DS and age-matched controls were geno-
typed. We observed gross morphological changes in
megakaryocytes and erythrocytes in the DS subjects
carrying the TREM2 R47H variant.
We also investigated the role of TREM2 in
phagocytosis using a human myeloid cell line
(THP1) and showed its presence in early and late
endosomes. Following silencing with an anti-sense
oligo-RNA, we observed significantly increased cell
death.
These findings have major implications for the
development of immunological or inflammatory cell
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Table 1
Human brain samples from Down’s syndrome (DS), Alzheimer’s disease (AD), and age-matched controls analyzed in this study
Case Category Age Gender Postmortem Braak Cause of death
number delay (h) stage
DS
DS1 DS 56 F 6 6 Not known
DS2 DS 76 F 18 6 Septicemia
DS3 DS 46 F 8 2 Not known
DS4 DS 52 M 24 6 Bronchopneumonia
DS5 DS 64 M 31 6 Not known
DS6 DS 66 F 26 5 Not known
AD
AD1 AD 86 F 86 6 Urinary tract infection/advanced Dementia
AD2 AD 88 M 81 6 Urinary tract infection/Addison’s disease and poor
immunity/vascular dementia/AD
AD3 AD 83 M 46 6 Bowel ischemia/hypothyroid/hypertension/AD/atrial
fibrillation/chronic kidney disease/vascular dementia
AD4 AD 88 M 22.3 5 Pneumonia/aortic stenosis/mixed dementia/left cerebellar
hemisphere hemorrhage
AD5 AD 70 M 71 6 Pneumonia/AD
AD6 AD 79 F 45.3 6 Cerebrovascular accident/dementia
Controls
C1 Control 45 F 43.3 0 End stage renal failure/diabetic nephropathy
C2 Control 66 M 10.3 5 Cerebrovascular disease/dementia
C3 Control 54 F 10.3 0 Metastatic myxoid liposacroma/bronchopneumonia
C4 Control 52 F 30.3 1 Bronchogenic cancer
C5 Control 75 F 24 2 Cancer of the ovary
C6 Control 66 F 29.3 2 Metastatic breast cancer
or drug-based therapeutic approaches to AD in DS,
which we discuss below.
MATERIALS AND METHODS
Subjects
Human brain tissues from controls (age 60 ± 15
years), DS (age 60 ± 15 years), and AD (age
82.0 ± 8.0 years) (n = 6 in each group) were pro-
vided by the Cambridge Brain Bank (Table 1). For
use of human brain tissue and serum samples, The
Cambridge Health Authorities Joint Ethics Commit-
tee granted ethical approval. Whole blood and serum
samples from human controls (n = 50), DS (n = 50),
and AD (n = 50) were collected for DNA and protein
analysis. Written consents were obtained from typi-
cally developing controls and all adults with DS with
capacity to consent. Verbal assent was obtained from
participants with DS lacking capacity and a written
assent was provided by an appointed consultee, in
accordance with the UK Mental Capacity Act (2005).
Ethics and research and development approvals were
granted by the National Research Ethics Committee
of East of England – Norfolk and Cambridgeshire and
Peterborough NHS Foundation Trust, respectively.
Blood collection and blood and bone marrow
slide preparation
We analyzed 50 cases of DS diagnosed at our center
during a three-year period from July 2012 to June
2015. Blood samples were collected into serum blood
collection tubes and serum immediately separated by
centrifugation at 2,465 g for 6 min at 4◦C, aliquoted,
and stored at –80◦C until analysis.
A drop of blood or bone marrow placed on a slide
was spread using a spreader as described in Dacie
and Lewis [26]. The slide was air-dried and fixed in
100% methanol and stored at 4◦C. Further investiga-
tions, including immunohistochemistry (IHC), were
performed on stored fixed slides as described later.
Biochemical and hematological profiles were ana-
lyzed by pathology laboratories at Addenbrooke’s
Hospital, Cambridge University Hospitals NHS
Foundation Trust, Cambridge.
Genotyping
Single nucleotide polymorphism (SNP) genotyp-
ing for TREM2 SNP, rs75932628, C-T encoding the
R47H variant was performed using the TaqMan®
allelic discrimination assay on a HT7900 sequence
detection system (Applied Biosystems), according
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to the manufacturer’s instructions. Genotyping suc-
cess rates were >96%. There were no inconsistencies
amongst 92 samples genotyped in duplicate. APOE
(2,/3 and 4) genotype was analyzed by Genotype
Facilities, East Anglia Medical Genetics Ser-
vice, Addenbrooke’s Hospital, Cambridge University
Hospitals NHS Foundation Trust, Cambridge.
Cell culture
THP-1 cell line
Human monocytic leukemia cell line THP1 (from
ATCC) was plated on PDL coated glass cover
slips in 24-wells plate at a density of 1.0 × 105
cells/mL with Dulbecco’s modified Eagle’s medium
(DMEM, Gibco), 10% fetal calf serum (FBS) and 1%
penicillin–streptomycin–fungizone. After 1–3 days
in vitro, cells were fixed with 80% ice-cold methanol
and analyzed by immunofluorescence or further func-
tional analysis was performed as described below.
THP1 cells and phagocytosis of rat red blood
cells
THP1 cells (passage 3–5) were seeded at a density
of 1.0 × 105 cells/ml in complete media (DMEM plus
10% FBS) in 6-well plates or on PDL coated glass
cover slips in 24-wells plate and allowed to adhere
for 24 h. Antibody-coated rat red blood cells (RBCs)
were added (10l containing 10 × 106 RBCs) to each
well; a slightly modified method was used previously
[27]. 24 h after the complete media and cells were
collected for western blotting (WB). PDL coated cov-
erslips were treated with (10l containing 1 × 105
rat RBCs) for 24 h, similarly as above and cells were
washed and fixed with 80% ice-cold methanol and
analyzed by immunofluorescence.
Transient transfection of THP1 cells with
TREM2 siRNA
THP1 cells (passage 3–5) were seeded at a den-
sity of 1.0 × 106 cells/ml in DMEM plus 10% FBS
in 6-well plates and allowed to adhere for 24 h before
transfection with TREM2 anti-sense RNA (siRNA
from Abmgood, Catalogue number: i525410). One
tube of TREM2 (2.5 nmol) siRNA oligo was dis-
solved in 125l of DEPC water to obtain final
concentration of 20 pM. 24 h following seeding,
the media was aspirated from each well, and the
cells were washed once with pre-warmed Dulbecco’s
Phosphate Buffered Saline (DPBS). The cells were
supplemented with OptiMEM (Life Technologies,
Paisley, UK) without any added FBS or antibiotics.
2 h following the addition of OptiMEM, the THP1
cells were transfected with 10 pmol of siRNA-
TREM2 or scramble siRNA against a non-targeting
control sequence (referred to as control cells), using
Lipofectamine 2000 (Life Technologies, Paisley,
UK) according to manufacturer’s protocol. The 10
pmol TREM2 siRNA concentration was chosen after
siRNA dose-response studies were performed (data
not shown). 24-h post-transfection, the media was
aspirated from each well, the cells were washed once
with pre-warmed DPBS, and complete media was
added to the wells. The cells were maintained in
complete media for a further 24–48 h. The extent of
siRNA-mediated silencing of the genes was assessed
and confirmed by IHC and WB.
Antibodies
The following primary antibodies were used
mouse monoclonal (MAB) anti-TREM2 (ab201621,
MM0942-42E14) and rabbit monoclonal (ab209814)
and other antibodies (Supplementary Table 1) from
Abcam (Cambridge, UK). The monoclonal anti-
A42 antibodies (6E10) (Signet laboratory) have
been described previously [21, 28] and other antibod-
ies used in this study are shown in Supplementary
Table 1. The following secondary antibodies were
used: biotinylated goat anti-rabbit and biotinylated
horse anti-mouse (both from Vector Laboratories,
1 : 250for IHC);AlexaFluor568-labeleddonkeyanti-
mouse, Alexa Fluor 488-labeled donkey anti-rabbit,
and Alexa Fluor 568-labeled donkey anti-goat (all
from Invitrogen, 1 : 1000 for immunofluorescence).
SDS-PAGE and western blotting
The HEK293T cell line was transfected with
human TREM2 cDNA (Human cDNA ORF clone,
NM 018965). Cell lysates from wild type HEK293
cells and TREM2 transfected HEK293 cells were pre-
pared. Similarly, protein lysates were prepared from
the temporal cortex and hippocampus of human brains
(n = 6), and human serum (n = 50 in each group).
20g protein samples were separated on 4–12%
Nu-PAGE® Bis-Tris (Bis (2-hydroxyethyl)-amino-
tris (hydroxymethyl)-methane) gradient gels (1.25 M
Bis-Tris pH 6.4, 30% acrylamide/bis), run with
NuPAGE® MES SDS running buffer (Lifetechnolo-
gies), and transferred to 0.45m pore size polyvinyli-
dene difluoride (PVDF) membranes (Invitrogen).
Membranes were incubated with the appropriate pri-
mary antibody in blocking buffer (1% milk in 0.1 M
R. Raha-Chowdhury et al. / Soluble TREM2 in AD Pathology in Down Syndrome 1147
tris saline buffer containing 0.1%Tween 20) for 24 h
at 4◦C and then washed three times with 0.1 M tris
saline buffer containing 1% Tween 20 (TBST) fol-
lowed by incubation for 1 h at room temperature with
HRP-conjugated secondary antibodies (anti mouse
IgG 1 : 3000, DAKO) or anti-rabbit IgG (1 : 3000;
DAKO) antibodies). Binding was detected with ECL
PluschemiluminescencereagentsandHyperfilmECL
(bothfromGEHealthcare). Immunoblotcontrolscon-
sisted of pre-adsorption of the antibody with an excess
of the immunogenic peptides (Abcam Ab174422),
that blocks the anti TREM2 antibody used in the
study (Abcam 201621), resulting in the absence of
immunoreactive bands in the membrane.
Immunoﬂuorescence
Brain sections, blood smears, or cells were
blocked using blocking buffer (0.1 M PBS, 0.3% Tri-
ton X100, 10% normal donkey serum) for 1 h at
room temperature, then incubated overnight at 4◦C
with primary antibody diluted in blocking buffer.
Alexa Fluor-conjugated secondary antibodies were
used for detection and samples counterstained with
4′6-diamidino-2-phenylindole (DAPI, Sigma). Sec-
tions were then mounted on glass slides with
coverslips using FluorSave (Calbiochem).
Microscopy
Bright field images were taken and quantified
using Leica imaging software and a Leica FW 4000
upright microscope equipped with a SPOT digital
camera. Fluorescence images were obtained using a
Leica DM6000 wide field fluorescence microscope
equipped with a Leica FX350 camera with x20 and
x40 objectives. Images were taken through several
z-sections and de-convolved using Leica software. A
Leica TCS SP2 confocal laser-scanning microscope
was used with x40 and x63 objectives to acquire
high-resolution images.
Image and statistics analysis
All sections for (IHC and WB) were performed in
triplicate. WB images were quantified using ImageJ
software (US National Institute of Health), normal-
izing all samples to loading controls. Values in the
figures are expressed as mean ± SEM. To determine
statistical significance, values were analyzed by Stu-
dent’s t-test. A probability value of p < 0.05 was
considered to be statistically significant.
RESULTS
Soluble TREM2 protein level declined in DS
serum with disease progression
As a first step towards determining possible roles
of TREM2 in DS, we investigated TREM2 protein
levels in human brain tissue and serum by WB using
anti-TREM2 mouse monoclonal antibody (MAB)
(ab201621, Supplementary Table 1).
To validate that TREM2 protein was recognized by
TREM2 antibody (ab201621), cell lysates obtained
from the HEK293 cell line transfected with Human
TREM2 cDNA was analyzed by WB. The anti-
body recognized bands of 25 kDa and ∼18 kDa,
respectively, in the cell lysates of these TREM2 over-
expressing HEK293 cells, and in control HEK293
cell lysates no bands were seen, as expected (Fig. 1a).
To investigate TREM2 protein expression in human
brain, tissue from the superior frontal cortex of
AD, DS, and age-matched controls brains (n = 6 in
each group), TREM2 protein was detected as non-
glycosylated 25 kDa and ∼18 kDa truncated bands.
There was an additional ∼50 kDa band visible which
may potentially be a TREM2 dimer (Fig. 1b). The
TREM2 levels (i.e., the 25 kDa bands) were high-
est in control, lower in DS and lowest in AD brains
(Fig. 1b, 1c; p < 0.001).
Serum samples obtained from DS, AD, and con-
trols (living subjects) were analyzed by WB. We
divided DS subjects into three age groups (younger
DS, n = 16, 30–39 years; middle aged DS, n = 20,
40–49 years; and older DS subjects, n = 8, 50–65
years—none of the younger DS subjects up to age
45 had developed clinical dementia). WB showed
that samples from younger DS subjects had ∼50 kD
and 25 kDa bands and a multiple banding pattern
between ∼7–18 kDa weights, which were possi-
bly due to truncation of the protein as a result
of ectodomain shedding, as described previously
[29] (Fig. 1e). More truncated TREM2 bands were
detected in DS serum compared to controls. Serum
TREM2 levels were significantly higher in younger
DS, lower in middle aged DS and lowest in the
older subjects (Fig. 1e, f; p < 0.001 when comparing
older versus younger DS). Similarly, serum TREM2
levels were lower in AD (n = 25, p < 0.001) when
compared with age-matched controls (n = 25) but
lowest in DS (Fig. 1h, i; p < 0.001). Anti--actin for
brain tissues and human anti-serum albumin anti-
body for serum were used as protein loading controls
(Fig. 1d, g, j).
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Fig. 1. TREM2 protein levels declined with Alzheimer’s diseases progression in Down syndrome. To validate the TREM2 antibody
(ab201621), the HEK293 cell line was transfected to overexpress human TREM2, cell lysates were analyzed by WB. The antibody recognized
a band of 25 kDa and ∼18 kDa in the TREM2 overexpressing HEK293 cell lysate, whereas in control HEK293 cell lysate no band was
seen (a). The WB analyses performed on postmortem human brain tissue (superior frontal cortex) showed that TREM2 levels were highest
in controls, significantly decreased in DS and lowest in AD brains (b & c, p < 0.0005). TREM2 serum levels were significantly increased
in young DS, lower in middle age, and lowest in the older subjects (e & f, p < 0.001 between older versus younger DS). Similarly, serum
TREM2 levels were lower in AD (n = 25), compared with age-matched controls (n = 25) and lowest in DS (h & i, p < 0.001). -actin and
human serum albumin were used as positive controls for brain tissue and serum samples, respectively (d, g, & j). Bonferroni-corrected
Student’s t-tests shown; (n = 8–25 per group). Error bars indicate SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, one-way ANOVA.
These data indicate that further truncation of serum
TREM2 following ectodomain shedding may be
age or disease related. Furthermore, in DS and AD
brain tissue, our results show that TREM2 protein
levels decrease in AD brain with age and disease
progression.
TREM2 protein is absent in senile plaques in DS
brain
We next attempted to visualize TREM2 expres-
sion using immunofluorescent staining on sections
of postmortem brains superior frontal cortex and tem-
poral cortex from AD, DS, and age-matched controls
(n = 6 in each group: 46 to 76 years, Table 1). Exten-
sive variation of TREM2 expression was observed in
different brain regions as well as between DS cases.
In the superior frontal cortex of control brain, anti-
TREM2 and anti-amyloid- (A40) co-localized in
pyramidal neurons and in small vesicles (Fig. 2a-
c). In DS brain sections, although many mature
senile plaques (SPs) with well-defined cores of
amyloid--42 (using A42, 6E10 antibody) protein
were observed, only small numbers of cells in the
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center of the SPs were positive for TREM2 (Fig. 2d-
g). In one DS case (DS6, 66 years old), only a very
limited amount of TREM2 protein was present in the
hippocampus (molecular grey matter) adjacent to the
dentate gyrus, and there was increased signal inten-
sity around the cortical neuron (Fig. 2f). Whereas
in another sample from a subject (DS2, 76 years
old) showed A42 positive plaques but there was no
TREM2 expression visible (Fig. 2g). Similarly, in
AD brain sections stained with TREM2 and A42,
TREM2 protein was not detected in SPs and only
found peripheral to the plaques (Fig. 2h-j). TREM2
protein expression was higher in control brains, lower
in AD and lowest in DS brains (Fig. 2k; p≤ 0.001).
High power DS brain images were captured with con-
focal microscopy. In a young DS subject (DS3, 46
years old), TREM2 protein was visible in the layer
V pyramidal neurons of the frontal cortex (Fig. 3a),
and in the periphery of SP (Fig. 3b-d). We have pre-
viously reported that TREM2 protein is expressed
in dentate gyrus granule cells of wild type mice
[21]. TREM2 protein was also observed in the cere-
bellar granule cell layer in DS brain (Fig. 3e, f).
These data suggest that TREM2 occurs in young
healthy pyramidal neurons and in granule cells, but
there is only very limited expression in damaged
(diseased) neurons and it does not co-localize with
A42-positive SPs.
TREM2 expression in a selective population of
phagocytotic microglia and macrophages in DS
and AD brains
Recent work has shown TREM2 to be involved in
microglial activity [30, 31] and the amyloid clearance
process. We therefore investigated TREM2 expres-
sion in microglia, macrophages and astrocytes in
control, AD and DS brains. In control brains, we
found no TREM2 co-localization with the astrocytic
marker GFAP (Fig. 4a). However, in AD brain sec-
tions GFAP positive astrocytes were present around
SPs and they appeared very granular and damaged
(Fig. 4b). In DS brain sections, activated astrocytes
were visible close to the SPs but no co-localization
with TREM2 was observed (Fig. 4c, individual panel
was shown in Supplementary Fig. 1a-c). We mea-
sured the relative intensity of TREM2 and GFAP and
although there was no difference in total TREM2 lev-
els around astrocytes, there were higher numbers of
activated astrocytes in AD brains compared to DS and
controls (Fig. 4d; p≤ 0.001).
We then stained brain sections with microglial
marker (Iba1) and TREM2. In control brains,
Iba1 positive microglia were visible in the cortex
(Fig. 4e-g; Supplementary Fig. 2a-c). TREM2 was
present in some cells close to blood vessels but
there was limited TREM2 expression in the rami-
fied microglia (Fig. 4f, g; Supplementary Fig. 2a-c).
In DS brains, TREM2 protein was found in sur-
viving cells around the SP (Fig. 4h; Supplementary
Fig. 1d-f). Iba1 positive activated microglia were
present in the brain parenchyma but there was limited
co-localization with TREM2 (Fig. 4h; Supplemen-
tary Figure 1d, f). In DS brain, soluble TREM2 was
observed to be present in a cell on the pial surface
of a macrophage phenotype in addition to a subset of
microglia within the cortex (Fig. 4i, j; note also small
vesicles shown by arrow head). In AD brain, activated
microglia were present near SPs in the cortex (Fig. 4k-
m; Supplementary Figure 2d-f) and limited numbers
of damaged microglia co-localized with TREM2 in
the periphery of SP (Supplementary Figure 2f) and
in the hippocampus (Fig. 4m; p≤ 0.01). The high-
est number of TREM2 positive cells was seen in
control brains and the lowest in DS brains (Fig. 4n;
p≤ 0.001).
As TREM2 protein was visible in peripheral
macrophages in post mortem brain tissue, we
therefore extended our search using anti-CD68
(phagocytotic macrophage/microglia marker), and
anti-TREM2 antibodies. In all brain sections,
TREM2 showed very strong co-localization with
CD68 (Fig. 4o-q, r; p≤ 0.001). In DS brain, red blood
cells (RBCs) were visible on the pial surface of the
cortex and TREM2 protein was found inside the brain
parenchyma (Fig. 4q). These data support the notion
that macrophages and red blood cells from blood ves-
sels can transport soluble TREM2 protein into the
brain parenchyma.
TREM2 protein observed in the brain
parenchyma close to blood vessels
To confirm the location of TREM2 in cells related
to peripheral blood vessels in the brain parenchyma,
we investigated the expression of DAP12 and the
macrophage marker CD68. DAP12 is a type-I trans-
membrane adapter protein that forms a molecular
complex with various receptors, including TREM2
[32]. In control brain sections, TREM2 and DAP12
were visible in neurons in the brain parenchyma
(Supplementary Figure 3a-c). To confirm neuronal
expression, brain sections were stained with TREM2
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Fig. 2. TREM2 protein is absent in senile plaques in DS brain. Double immunofluorescence staining was performed in the temporal cortex
of normal control brain tissue by using the rabbit polyclonal anti-A40 (green), mouse monoclonal anti-TREM2 (red), and DAPI for nuclei
(Blue). A40 immunoreactivity was visible in pyramidal neurons (a), TREM2 in the cell body (b), and both proteins co-localized in the
perinuclear location in pyramidal neurons (c). In DS (DS6), layer III temporal cortex sections stained for A42 (green) and TREM2 (red)
showed many mature plaques (d & e). TREM2 was rarely present in the core of the plaques (d) and in neurons (f). Further staining on a
different case (DS2) showed that A42 did not co-localize with TREM2 (g). In AD brain, TREM2 protein was visible around the plaques
(h-j). A42 level was highest in AD brain (k, p < 0.0001) and TREM2 level was lower in surviving neurons compared to control and AD
brain (K, p < 0.01). The scale bar in a-e = 50m, f = 25m, and g = 40m. These data represent the mean ± S.E from three independent
experiments. Error bars indicate SEM. ∗p < 0.01, ∗∗p < 0.001, ∗∗∗p < 0.0001.
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Fig. 3. Confocal images of senile plaques and cerebellar granule cells in DS brain. Confocal microscopy analysis was performed on DS brains
sections, using anti-A42, anti-TREM2 and counterstained with DAPI (blue). DS brain sections from frontal cortex revealed TREM2 protein
was visible in the layer V pyramidal neurons (a), characteristic neuritic plaques stained with A42 (b-d), and limited TREM2 expression
was seen in the SP (c, d). A high-power image showed TREM2 (green) appeared to be expressed in the cerebellar granule cells (e, f). Scale
bar in a-d = 25m, e = 50m, f = 15m.
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Fig. 4. TREM2 expression in a selective population of phagocytotic microglia and macrophages in DS and AD brains. Brain sections were
stained with the astrocytes marker GFAP (green, indicated with arrow in astrocytes) and TREM2 (red, with arrow head) (a-c). In control brain
section, TREM2 was seen in the in the neurons surrounded by GFAP positive astrocytes (a), in AD brain sections astrocytes were granular,
fragile and seen close to the plaques (b), whereas in DS brain activated astrocytes were present in the vicinity of the amyloid plaques (c).
Highest expression of GFAP positive astrocytes was found in AD brain (d, p < 0.001). Iba1 positive ramified microglia were seen in control
brain (e-g), while activated Iba1 (green) positive microglia were visible in DS brain (h) and a TREM2 positive macrophage was visible on
pial surface and small vesicular particle (i), co-localized with TREM2 and Iba, showed with arrow head (j). In AD brains, a small number of
Iba1 positive microglia co-localized with TREM2 close to senile plaques (k, l), and in hippocampus (m), indicated with arrow in microglia
and arrow head in neurons. There were more microglia positive for Iba1 in control brain compared to DS and AD (n, p < 0.0001). In the
pial surface and in blood vessels, TREM2 (green) was visible in peripheral macrophages where it co-localized with the macrophage marker
CD68 (red) (o-q). In DS brain, strings of blood cells were visible in the brain parenchyma that co-localized with TREM2 (q) and highly
significantly (r, p < 0.0001). Scale bar in a-c = 25m, e-g & q-U = 50m, h-j = 20m. Image intensity measured by Image J (d, n, and r).
Error bars indicate SEM. ∗p < 0.01, ∗∗p < 0.001, ∗∗∗p < 0.0001.
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and a neuronal marker (NeuN), which were found
to co-localize (Supplementary Figure 3d). In DS and
control brain sections, TREM2 was found in perivas-
cular macrophages close to blood vessels (Fig. 5a-c).
DS brain sections were stained with anti-TREM2 and
anti-CD68, and were found to co-localize (Fig. 5d).
TREM2 positive cells were observed to be in direct
contact with the pial surface and only a small subset
co-localized with Iba1 positive cells (Supplementary
Figure 3e-f). DS brain sections close to the blood
vessels were stained with anti-A42 and anti-TREM2
and imaged with confocal microscopy. A42 was vis-
ible in the brain parenchyma and blood cells whereas
TREM2 was seen in cells in close proximity to blood
vessel walls (Fig. 5e-g).
Haplotype co-relation between TREM2 and
APOE in DS
We performed single nucleotide polymorphisms
(SNPs) analysis for the TREM2 (R47H, C/T) muta-
tion and APOE genotype (2, 3, and 4 alleles) in
our DS DNA from blood samples (n = 50). The fre-
quency of the TREM2 R47H (T allele) mutation was
0.046-only two subjects out of 44 carried the muta-
tion; a similar frequency was previously reported
in AD and older population [16]. The frequency of
APOE alleles 2 (0.11) and 4 (0.15) were greater
in DS, whereas 3 (0.74) was lower compared to
previously published studies on AD (2, 0.066; 3,
0.85; and 4, 0.08) [33]. None of DS subjects were
homozygous for the APOE4 allele. One DS subject
(DS55, 39 years old) with TREM2 R47H (T allele)
was heterozygous for APOE (3/4) and another DS
subject (DS18, 32 years old) was homozygous for
APOE (3/3). Both of them did not have clinical
dementia, and may have been too young to show
clinical symptoms. There was a positive co-relation
between the TREM2-C allele and APOE 2 allele as
a protective haplotype, but the number of DS sam-
ples available to study were too limited to infer any
statistical significance.
TREM2 was observed in erythromegakaryocytes
and in platelets, suggesting a myeloid origin
There is an increased risk of leukemia in adults
with DS in addition to a variety of other hematological
abnormalities that have been reported [9]. Therefore,
we analyzed TREM2 expression in blood smears
from DS subjects (n = 50, from different age groups
30–65 years) and imaged with confocal microscopy.
DS and control blood smears were co-labeled
with TREM2 and an erythrocyte plasma membrane
marker glycophorin. Both proteins were found to co-
localize in RBCs membranes suggesting that TREM2
was expressed on surface of RBCs (Fig. 6a-f). There
was stronger TREM2 expression around the RBC
plasma membranes, in platelets and in neutrophil
plasma membrane in the control samples (Fig. 6a-c)
compared to DS samples (Fig. 6d-f, o; p≤ 0.001).
Additionally, TREM2 was observed scattered and
extra-corporally to RBCs and within the cell bodies of
mononucleated cells (MNC) in DS samples (Fig. 6d-
f). A classic dysmorphology (bi-lobed neutrophils)
with significantly higher TREM2 protein around the
MNC was frequently observed in young DS blood
smears (Fig. 6h-j), whereas normal neutrophils pos-
itive for TREM2 were found in controls (Fig. 6 g).
The blood smear from a young DS subject (DS1, 30
years old) showed more TREM2 protein expression
within RBCs (but not around the erythrocyte plasma
membrane) and around the neutrophils (Fig. 6d, h).
Two young DS participants’ blood sample smears
(DS18, aged 32 years and DS55, aged 39 years,
with the TREM2 R47H, T mutation) showed abnor-
mally shaped RBCs in their smears (Fig. 6e, f; and
see below), with abnormal accumulation of TREM2
around the MNCs (Fig. 6i, j). DS55 was heterozy-
gous for APOE genotype (E3/E4) and displayed an
abnormal erythrocyte phenotype compared to DS18
(3/3 genotype) (Fig. 6i). Another blood smear of
a young DS participant (DS2, 30 years old nega-
tive for R47H mutation and carrying APOE (3/4
genotype) when stained with TREM2 and APOE or
A42, showed that both proteins were co-localized
in platelets and around the MNC (Fig. 6k, m, p, q;
p≤ 0.001). A confocal micrograph of blood smear
from DS2 showed large numbers of small particle
(like vesicles or exosomes) around the platelets and
MNCs. To confirm this, we stained some other slides
with exosome markers CD9 or CD63 and TREM2,
and both co-localized, indicating that TREM2 could
be transport by plasma exosomes particles (Fig. 6n).
RBCs appeared macrocytic and both of the DS
participants (DS18 and DS55) who were positive for
the TREM2 variant (R47H mutation, C/T variation),
had significantly higher mean red-cell volumes and
low hemoglobin, white cell (3.6 × 103/L) and platelet
counts (50 × 109/L), and showed abnormal shape
RBCs (Fig. 6l, p≤ 0.001). These findings indicated
that TREM2 protein may be essential for normal
development of RBCs and for transporting soluble
proteins.
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Fig. 5. TREM2 protein enters in the brain from blood vessels via macrophages. Immunofluorescence staining was performed with polyclonal
rabbit anti-DAP12 (green), monoclonal anti-TREM2 (red) antibodies, and DAPI (Blue). In control brain sections, DAP12 was visible in the
brain parenchyma (a), whereas TREM2 was found in the perivascular macrophages and close to the blood vessels in DS brain (b). In DS
brain a TREM2 positive macrophage was seen in blood vessels (c). DS brain sections were stained with TREM2 and CD68, showed that
TREM2 protein carried by RBCs (d). A confocal micrograph showed A42 (green) was visible in the parenchyma and in the blood cells
whereas TREM2 (red) was seen in the macrophages close to the blood vessels (e-g). Scale bar in a-b = 70m, c-d = 50m, and e-g = 20m.
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Fig. 6. TREM2 was observed in erythromegakaryocytes and in the platelets suggesting a myeloid origin. Confocal micrograph images taken
of DS and control blood smears, were stained with anti-TREM2 (green) and anti-glycophorin (red), a red blood cell (RBC) membrane marker.
TREM2 protein (green) was present around the erythrocytes membrane (a-c). There was a stronger TREM2 (green) expression around the
RBCs in the control blood smear (a) than in DS (d-f). Additionally, analyses on the DS blood smears revealed the presence of scattered
TREM2 (green) outside mononucleated cells (g-j). In two young DS subjects that were carrying TREM2 C/T variant (R47H mutation, DS18,
and DS55), blood smears contained abnormal shape of the (i-j) and soluble TREM2 and APOE around the neutrophil (k). In mutant carrier
DS 55 (mutant carrier) showed abnormal shape RBCs and a very faint TREM2 expression was seen in the center of RBCs and membrane
bound A42 (green) was visible (l). In young DS2 (APOE4 carrier) carried fragmented platelets surrounded by vesicles positive for TREM2
(m) and co-localized with exosome marker CD9 (n). Bar diagrams: TREM2 level was lower in mutant DS (o), A42 and APOE levels was
higher in older DS (p & q, ∗∗∗p < 0.0001) Scale bar in a-f, k&l = 20m, g-j = 10m, m&n = 5m.
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TREM2 is expressed in the human bone marrow
myeloid cells and mesenchymal stem cells and it
participates in erythro-phagocytosis
To confirm that TREM2 is expressed in human
bone marrow megakaryocytes, a DS bone marrow
slide was stained with TREM2 and a well-
known megakaryocyte marker CD42b. TREM2 was
expressed in bone marrow megakaryocytes (Fig. 7a).
Human primary mesenchymal stem cells (MSC) were
stained with TREM2 and CD42b, which showed
that TREM2 was present in human MSC (Fig. 7b),
and both proteins co-localized in a human mono-
cyte/myeloid cell line, THP1 (Fig. 7c). As RBCs
were engulfed by microglia/macrophages in human
brain sections as seen in Fig. 4p and q, we investi-
gated whether TREM2 was involved in erythrocyte
phagocytosis using the THP1 cell line (Fig. 7c, d).
THP1 cells were treated with freshly harvested IgG
coated rat RBCs (Fig. 7e-g), which was previously
described method used to investigate RBC phagocy-
tosis [27]. We confirmed that TREM2 protein was
present in RBCs, which then participated in phago-
cytosis and endocytosis. RBCs were engulfed by
the THP1 cells within 4 h and membrane bound
TREM2 was visible (Fig. 7e-g) and TREM2 co-
localized with EEA1 (an early endosome marker)
and LAMP1, (a late endosomal marker) (Fig. 7h, i).
Cells were harvested and TREM2 protein analyzed
by WB showed that the TREM2 levels increased at
least four-fold after RBCs treatment suggesting that
TREM2 protein was present in RBCs (Fig. 7m, n;
p≤ 0.001).
Knock down of TREM2 using siRNA in THP1
cells
We have previously reported that TREM2 pro-
tein is important for cellular proliferation [21]. To
further investigate the role of TREM2 in cellular pro-
liferation, THP1 cells were transfected with human
TREM2 anti-sense oligonucleotides for 24–48 h,
which resulted in an increase in cell death. After 48 h,
cells were stained with TREM2, CD42b, and DAP12
antibodies and only very faint TREM2 expression
was visible (Fig. 7j-l). Cells were harvested and a
WB analysis performed using mouse anti-TREM2
MAB (ab201621) which showed TREM2 expres-
sion in control cells (treated with scrambled SiRNA)
but not in TREM2-siRNA treated cells (Fig. 7o, p;
p≤ 0.001).
DISCUSSION
People with DS have intellectual disability, pre-
mature aging, and have a high risk for developing
AD dementia pathology [34–39]. The mechanism of
the early onset of AD pathology is not fully under-
stood but the over-expression of certain genes on
chromosome 21 including APP and oxidative stress-
related genes including Cu/Zn superoxide dismutase
(SOD1), Ets-2 transcription factors, and S100 play
crucial roles [40, 41]. Abnormalities in the immune
system are also seen in people with DS and may
also participate in the pathogenesis of AD. Various
immunological and hematological abnormities are
more common in DS and suggest that inflammation
and activation of innate immunity are early events in
DS [42]. These include susceptibility to autoimmune
diseases, recurrent infections, mild to moderate T and
B-cell lymphopenia, defective neutrophil chemo-
taxis. Adults with DS are prone to myeloid leukemia
but also have a variety of blood abnormalities includ-
ing leukopenia, macrocytosis, elevated mean red-cell
volume, and persistent abnormal erythrocytosis [43].
We investigated the role of TREM2 in DS and its
relationship to AD to understand the contribution of
innate immunity to the pathogenesis of dementia.
TREM2 is primarily expressed in various tissue
macrophages, monocyte-derived dendritic cells and
osteoclasts [13]. The R47H mutation in the TREM2
gene correlates with a substantial increase in the risk
of developing AD [15, 16, 44]. The identification of
this novel variant in the gene encoding TREM2 has
refocused attention onto myeloid defects and their
potential as a contributory factor in AD and dementia
in DS [45–47].
Using human brain sections from AD and DS
we provide evidence for the first time that soluble
TREM2 originates in bone marrow, is transported
to the brain by a subset of macrophages (possi-
bly transported via exosomes), before being taken
up by microglia. We also demonstrated impaired
trafficking of TREM2 to the plasma membrane of
erythrocytes, which may ultimately impair amyloid
clearance mechanisms and result in an increased rate
of plaque deposition.
It was reported that soluble TREM2 is increased
in the cerebrospinal fluid in AD in a disease pro-
gression dependent manner [48]. We discovered that
TREM2 protein levels were significantly higher in
serum compared to brain lysate and which correlated
with disease progression in DS. These character-
istics could make soluble TREM2 an ideal serum
R. Raha-Chowdhury et al. / Soluble TREM2 in AD Pathology in Down Syndrome 1157
Fig. 7. TREM2 protein is involved in phagocytosis and is required for myeloid cells survival. In human bone marrow, TREM2 (green)
protein was expressed in myeloid progenitor cells and co-localized with mesenchymal cell markers anti-CD42b (a). Similarly, to human
mesenchymal stem cells (MSC), both TREM2 (red) and CD42b (green) were present (b), and showed some co-localization in monocytic
cell line THP1 (c). A bright field image of normal THP1 cells (d) and after 24-h post-treatment with rat RBCs showed total phagocytosis of
RBCs inside the THP1 cells (e-f) and co-localization with CD42b (g). RBC-treated THP1 cells were stained with TREM2 and found to be
co-localized with EEA1 (green) (an early endosome marker) (h) and LAMP1 (a late endosomal marker) (i), suggesting that TREM2 protein
participates in endocytosis and phagocytosis. WB analysis was performed with rat-RBC treated and untreated THP1 cell lysate. TREM2
protein levels increased at least four-fold post-RBC treatment (m & n, p < 0.0001). THP1 cells were transfected with human TREM2 anti-
sense oligonucleotides, cells were stained with anti-TREM2 and anti-DAP12 antibodies. Very faint TREM2 expression was visible (j-l).
Cells were collected and a WB analysis was performed with an anti-TREM2 antibody. TREM2 expression was visible in the control cells
but not in the siRNA treated cells (o & p, p < 0.0001). Error bars indicate SEM. ∗∗∗p < 0.0001. The scale bar in a-c and g-i = 25m, d-f and
j-l = 50m.
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biomarker to assess disease progression in AD [49].
We have shown for the first time that there was a sig-
nificant reduction of serum TREM2 levels in older DS
subjects (who were affected by AD dementia pathol-
ogy) compared with younger ones, and in addition, it
was even lower than in sera of AD patients.
Although many published papers have reported
TREM2 protein expression in microglia [50–53],
we showed for the first time that soluble TREM2
protein was present in neurons in human DS (and
control) brains, particularly in the cerebellar gran-
ule cells and in hippocampal neurons. We hypothesis
that this is soluble TREM2 that has entered neurons
and is involved in neuroplasticity and neuroprotection
[21]. In postmortem brain sections of DS and AD,
we showed minimal TREM2 expression near senile
plaques in frontal and entorhinal cortices. With dis-
ease progression, large swollen dystrophic neurites
and A42 positive SP were seen but TREM2 protein
was absent in SP.
In AD brain, however, some microglia were pos-
itive for TREM2 protein, but they displayed less
microglial activation and they had not engulfed A
plaques. This may have impacted on the density of
A plaques and thus promoted diffuse A structures
that are thought to be more neurotoxic and thus con-
tributing to the accumulation of classic AD pathology
[23, 31, 50]. These findings highlight a crucial role
of TREM2 in maintaining central nervous system
homeostasis [47].
The presence of TREM2 in oligodendrocytes, the
white matter tract of the olfactory bulb, corpus cal-
losum, and striatal bundles indicates that TREM2
protein may have a role in myelination [21], imply-
ing that the lack of functioning TREM2 could be
a contributing mechanism in demyelination deficits
seen in DS which would increase the susceptibility
for neuronal loss. TREM2 protein has been found
to be dysregulated in other demyelinating disorders
such as Nasu–Hakola disease, multiple sclerosis, and
amyotrophic lateral sclerosis [54, 55]. Myelination
defects are one of the features of DS children [56]
that may continue into adulthood, with the potential
to accelerate neuronal loss and premature aging and
contributing to cognitive impairment.
There is a highly organized innate immune
response during the early stages of inflammation
characterized by the expression of various immuno-
logical proteins in the circumventricular organs,
choroid plexus, and other structures lacking the pro-
tection conferred by the blood-brain barrier [57, 58].
The response extends progressively, affecting
microglia and macrophages across the brain
parenchyma, and it has the potential to lead to the
onset of an adaptive immune response [59, 60].
Macrophages are key cells in driving the innate
immune response and form a heterogeneous popula-
tion that possesses tissue-specific roles [47]. These
cells display remarkable plasticity with functions
that include the SP clearance response mediated
by innate immune cells [61]. TREM2 protein was
highly expressed in peripheral macrophages that
were close to the ventricles and subarachnoid space.
Although microglia/macrophages were clearly vis-
ible in DS and AD brain tissue and they may be
involved in phagocytosis and clearance of A pro-
tein, TREM2 more abundantly co-localized with
CD68 (macrophage marker), supporting the notion
that macrophages have the ability to transport solu-
ble TREM2 into brain parenchyma and be involved
in phagocytosis.
The expression of TREM2 in myeloid cells, even in
erythromegakaryocyte progenitors, strongly supports
an intrinsic immune factor involvement in aging and
abnormal cellular processes in aging in DS. Soluble
TREM2 protein carried by platelets and erythro-
cytes from the periphery enters brain parenchyma
via a subset of phagocytic microglia/macrophages
and/or exosomes. We confirmed that TREM2 protein
was carried by plasma exosomes (small vesicles) by
staining blood smears with known exosome mark-
ers (CD9 and CD63), as both markers co-localized.
Recently when we were preparing this manuscript a
paper published showed a very elegant transcriptional
single cell sorting of immune cells and identified
novel microglia associated with neurodegenerative
diseases (DAM) [62]. We may have identified same
subset of microglia/macrophages (DAM); however,
our data did not suggest that this subset of microglias
were disease associated, but instead could be disease
protective.
In addition, the TREM2 (R47H) mutation (which
has been strongly linked with an increased risk of
AD) was found in two DS subjects and in both we
observed gross morphological changes in megakary-
ocytes and erythrocytes. In erythrocytes, we also
discovered impairment of TREM2 trafficking to the
erythrocyte plasma membrane that could influence
the amyloid clearance mechanism thought to be
important in AD pathogenesis. These two subjects,
positive for the TREM2 R47H mutation, also man-
ifested a significantly higher mean red-cell volume
that may reflect enhanced erythropoiesis in response
to impaired oxidative metabolism.
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Another key protein involved in AD and DS is
apolipoprotein E (APOE), which imposes a major
genetic risk factor with 60–80% of AD affected indi-
vidual having at least one APOE 4 allele [63, 64].
APOE 4 carriers develop A plaques earlier than
non-carriers, and APOE 4 protein appears to influ-
ence A aggregation and the rate of A clearance
from the brain. We found young DS subjects het-
erozygous for the APOE 4 haplotype carried more
TREM2 and APOE protein around neutrophils than
in older DS subjects. In DS subjects (n = 47), 31%
of DS were heterozygous for the APOE 4 allele
and none were homozygous. The APOE 2 allele is
associated with a decreased risk of AD [65, 66]. The
frequency of 2 alleles in DS was higher (20%), and
interestingly nearly all DS subjects above 50 years of
age of were either carrying 3/3 or 3/2; there was
one exception of a DS subject above 50 years of age
(55 years old) with a 3/4 genotype and who had
clinical dementia. As we have shown that younger
DS have higher serum TREM2 protein levels than
older DS, this finding suggests that TREM2 protein
is neuroprotective and may act as a trophic factor.
To our knowledge, this study is the first to show
evidence that peripheral TREM2 originates from
bone marrow derived stem cells. We also confirmed
(as we had previously reported) a phagocytotic role
of monocytes [21] by using a myeloid/monocyte
cell line (THP1) treated with rat RBCs and where
both an early endosome marker (EEA1) and a
late endosome marker (LAMP1) co-localized with
TREM2 in the process. We also showed significantly
increased TREM2 protein levels after erythrophago-
cytosis using immunofluorescence and WB. These
data confirmed that TREM2 protein is carried by
RBCs.
Conclusion
In this paper, we have confirmed that TREM2
protein originates in megakaryocytes, it is a serum
protein transported in blood vessels by erythro-
cytes, and it migrates across the wall of ventricles
to enter brain parenchyma. Individuals with DS
show myeloid cell abnormalities from birth that are
likely to affect their bone density (osteoclast dys-
function) and myelination, and later in life the lack
of functioning TREM2 protein may accelerate neu-
ronal cell loss, contributing to the aging process
and neuroinflammation. As first proposed by Hardy
and Selkoe, the “amyloid cascade” hypothesis pur-
ports that mis-metabolism and subsequent deposition
of A peptides as amyloid- plaques are principle
etiopathological events in AD [67, 68]. We propose
the “myeloid hypothesis”, an additional conflating
mechanism unique to DS where myeloid cell defects
due to aneuploidy (impairment of protein transport,
myelination and innate immunity) accelerate disease-
related processes that lead to earlier onset of the
pathology of AD. We have shown that TREM2 plays
a critical role in this aging process. This hypothe-
sis would explain why AD pathology occurs some
15 to 20 years earlier in the DS population. Under-
standing the molecular mechanisms and identifying
critically important of TREM2 proteins involved
in neuroprotection may reveal novel therapeutic
targets.
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